Recce Pharmaceuticals' R327G Shows Promise in Phase II ABSSSI Trial
核心洞察
Recce Pharmaceuticals' Phase II trial of R327G for ABSSSI reaches a milestone with 20 of 30 patients dosed, indicating strong progress.
Interim data reveals that all patients treated with R327G achieved either a complete cure or notable improvement, demonstrating promising efficacy.
The trial remains on track for completion by the end of 2024, potentially leading to a new synthetic anti-infective topical therapy.
Recce Pharmaceuticals Ltd is nearing completion of its Phase II trial evaluating RECCE® 327 topical gel (搜索) (R327G) for treating acute bacterial skin and skin structure infections (搜索) (ABSSSI). Interim data from the trial, which has dosed 20 of the planned 30 patients, indicates promising efficacy and a favorable safety profile for R327G.
Positive Outcomes Observed
The interim results showed that all patients treated with R327G experienced either a complete cure or notable improvement. Importantly, no serious adverse events (SAEs) were reported, suggesting a strong therapeutic response and safety.
Expert Commentary
"These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies," said Alan W Dunton, MD, Chief Medical Advisor of Recce Pharmaceuticals. "Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections."
Trial Progress and Market Potential
The trial is on track to be completed by the end of 2024. Recce Pharmaceuticals aims to deliver a synthetic anti-infective topical therapy to address ABSSSI, a market projected to reach $26 billion by 2032. The non-DSMB's unanimous endorsement supports R327G's continued development and regulatory evaluation.
About RECCE® 327 (R327)
RECCE® 327 (R327) is a broad-spectrum, synthetic polymer anti-infective being developed for serious and potentially life-threatening infections caused by Gram-positive and Gram-negative bacteria, including superbug forms. It has received Qualified Infectious Disease Product designation from the FDA, granting Fast Track Designation and 10 years of market exclusivity post-approval.